Companies › RAPT Therapeutics, Inc., a member of the GSK plc group of companies
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RPT904 anti-IgE monoclonal antibody | IGHM | Phase 2 | Immune System Diseases | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07220811 | RPT904 | Phase 2 | Immune System Diseases | Immunology | Mar 2027 |
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) AnaptysBio Q32 Bio Chengdu Kangnuoxing Biopharma Ashibio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.